Symbols

ADMA

ADMA Biologics·NASDAQ

--(--)

ADMA fundamentals

ADMA Q4 2025 Earnings

ADMA Biologics (ADMA) released its earnings on Feb 25, 2026: revenue was 139.16M (YoY +18.39%), missed estimates; EPS was 0.2132 (YoY +51.31%), beat estimates.

Revenue / YoY

139.16M

+18.39%

EPS / YoY

0.2132

+51.31%

Report date

Feb 25, 2026

ADMA Earnings Call Summary for Q4,2025

Revenue Growth: 20% YoY to $510 million, with ASCENIV contributing 51% of revenue.
Gross Margin Expansion: 57.4% in 2025, targeting 63.8%+ in 2026.
Supply Chain Strength: >280 plasma centers secured, third-party supply agreements exceeding expectations.
Pipeline Momentum: SG-001 pre-IND submission planned for 2026, targeting $300-500 million peak revenue.
Financial Guidance: 2026 revenue >$635 million, EBITDA >$360 million,2027 revenue >$775 million, EBITDA >$455 million.

Earnings

EPS

Revenue

Revenue & Expenses

ADMA has released its 2025 Q4 earnings report, with revenue of 139.16M, reflecting a YoY change of 18.39%, and net profit of 49.38M, showing a YoY change of -55.87%. The Sankey diagram below clearly presents ADMA's revenue sources and cost distribution.

Key Indicators

ADMA Biologics (ADMA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ADMA Biologics (ADMA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ADMA Biologics (ADMA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ADMA Biologics (ADMA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown